Momcozy MaxSupport Nursing Pillow: Easier Nursing with Certified Safety and Ergonomic Design
New release aims to reduce strain, improve latching, and support healthier, more secure breastfeeding through certified-safe materials and an upgraded support structure.
New York, NY, May 30, 2025 (GLOBE NEWSWIRE) -- Momcozy, a global maternity care brand known for its innovation and dedication to maternal wellness, introduces the MaxSupport Nursing Pillow collection—an ergonomic, memory foam-based system designed to enhance comfort and safety for breastfeeding mothers. This launch is part of Momcozy's mission to make healthier, easier nursing a reality for every parent.Firm Support with Memory Foam Comfort
At the heart of every MaxSupport pillow is 45D high-density memory foam, selected for its ability to gently contour to the body while retaining structure. Unlike traditional fiber-filled pillows that lose shape over time, MaxSupport offers a resilient foundation that feels like resting on a mini high-quality mattress.
Its 28% wider surface provides enhanced arm and upper-body support—minimizing shoulder tension and promoting natural feeding alignment, especially during extended sessions.
Certified Safety That Meets 2024 Federal Standards
In response to the 2024 CPSC safety regulations, the MaxSupport Nursing Pillow is fully engineered to meet the latest U.S. federal safety standards. The pillow's certified firmness, safe feeding angles, and protective side barrier are designed to reduce the risks of suffocation and falls—giving moms peace of mind during every feeding.
All MaxSupport models are made with CertiPUR-US® certified memory foam and OEKO-TEX® certified fabrics, ensuring the materials are non-toxic, skin-friendly, and safe for babies and mothers alike.
Built-In Safety Features for Confident Nursing
A softly contoured side safety fence surrounds the nursing area to help secure the baby in place, reducing the chance of rolling or slipping. This, combined with the adjustable height options and removable waist and arm support cushions, allows for full customization based on body type, feeding position, or postpartum recovery needs.
These ergonomic enhancements are designed to reduce back and neck strain, support better latching, and help alleviate common breastfeeding discomforts like nipple soreness due to poor positioning.
Two Models, One Purpose: Better Breastfeeding Support
The MaxSupport collection includes two tailored versions:
Momcozy Original MaxSupport Nursing Pillow – Essential Set ($54.99)
CozyPro MaxSupport Nursing Pillow – Upgraded Set ($69.99)
The Essential Set features all core ergonomic and safety innovations, while the CozyPro version includes enhanced premium fabric finishes for moms seeking a touch of elevated comfort and style. Both models are built to retain their shape over time, making them ideal for long-term, daily use.
Designed by Moms, Backed by Experts
The MaxSupport line was developed through real insights from mothers and professional feedback from healthcare advisors. Whether used during cluster feeding, nighttime nursing, twin feeding, or bottle support, the pillows are crafted to adapt to real-life parenting scenarios.
Momcozy's thoughtful design ensures that support doesn't fade over time, but continues to deliver relief, alignment, and comfort through each stage of the breastfeeding journey.
Comfort Is Care: A Brand Mission in Action
The launch of the MaxSupport Nursing Pillow reflects Momcozy's broader commitment to supporting parents through intuitive, functional, and medically informed maternity products. Alongside its popular wearable breast pumps, maternity apparel, and wellness tools, MaxSupport underscores the brand's belief that comfort is a form of care—and every mother deserves both.
Exclusively available at momcozy.com, the MaxSupport Nursing Pillow is more than a feeding accessory—it's a trusted daily companion for healthier breastfeeding, safer positioning, and an all-around better experience.
#MomcozyMaxSupportNursingPillow #MaxSupportNursingPillow #CertifiedComfortForMomsAbout Momcozy
Momcozy is a global maternal care brand dedicated to enhancing the lives of mothers and babies through science-backed, comfort-focused solutions. From pregnancy to postpartum, Momcozy creates practical, emotionally attuned products designed to meet the real-world needs of modern parenting.
CONTACT: Anna Jiang Momcozy pr at momcozy.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
37 minutes ago
- Bloomberg
Tom Cruise's Final ‘Mission Impossible' Tops China Box Office
Mission: Impossible – The Final Reckoning posted the biggest opening for a US film in the country this year, defying trade and geopolitical tensions between Washington and Beijing. Paramount Global 's eighth installment in the action franchise earned $25.2 million across 11,847 locations in China during the opening weekend, the studio said in a statement. The film is likely to become the top-performing US release in the country for 2025, with Warner Bros Entertainment Inc. 's A Minecraft Movie so far holding the lead with about $29 million since its April 4 debut, according to ticketing platform Maoyan.
Business Upturn
an hour ago
- Business Upturn
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
By GlobeNewswire Published on June 2, 2025, 10:15 IST Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormone therapy versus hormone therapy alone, with positive trend in overall survival (OS) 1 Pluvicto is already approved for metastatic castration-resistant prostate cancer (mCRPC) and now shows potential in patients in an earlier disease setting 1,2 Novartis to present results at an upcoming medical meeting and, based on FDA feedback, will submit for regulatory review in the second half of the year Novartis is investigating a broad portfolio of RLTs in advanced cancers, including breast, colon, lung and pancreatic and is investing in multiple manufacturing facilities, with industry-leading infrastructure to accelerate delivery of RLTs to patients Basel, June 2, 2025 – Novartis today announced topline results from a pre-specified interim analysis of the Phase III PSMAddition trial. The trial met its primary endpoint with a statistically significant and clinically meaningful benefit in radiographic progression-free survival (rPFS) with a positive trend in overall survival (OS) in patients with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC) treated with radioligand therapy (RLT), Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan), in combination with standard of care (SoC) versus SoC alone1. In PSMAddition, the SoC is a combination of androgen receptor pathway inhibitor (ARPI) therapy and androgen deprivation therapy (ADT)3. Almost all mHSPC patients ultimately progress to metastatic castration-resistant prostate cancer (mCRPC)4. There is a need for additional treatment options with novel mechanisms of action that further delay progression, prolong OS and improve disease control compared to the current SoC, while showing a favorable safety and tolerability profile. 'The progression from metastatic hormone-sensitive prostate cancer to castration-resistant disease remains a formidable challenge that can profoundly impact the survival of patients,' said Shreeram Aradhye, M.D., President, Development and Chief Medical Officer at Novartis. 'These results further strengthen our confidence in Pluvicto as a PSMA-targeted radioligand therapy. Following the recent FDA approval based on the PSMAfore trial in metastatic castration-resistant prostate cancer, these data suggest using it in an earlier disease setting could advance care and address a significant unmet need for hormone-sensitive prostate cancer patients.' This is the third positive read-out for Pluvicto in a Phase III trial, following the VISION and PSMAfore studies5,6. Results from PSMAddition in mHSPC show potential for treatment in an earlier setting with Pluvicto, which was recently granted US Food and Drug Administration (FDA) approval for earlier use in mCRPC, based on results from PSMAfore1,2. Novartis is harnessing the innovation of world-class scientists, strategic partnerships and one of the industry's most competitive pipelines to explore the potential of new, targeted therapies and precision medicine platforms to address the greatest unmet needs in prostate cancer. Data will be presented at an upcoming medical meeting and, based on FDA feedback, will be submitted for regulatory review in the second half of the year. About PSMAddition study PSMAddition (NCT04720157) is a Phase III, open-label, prospective, 1:1 randomized study comparing the efficacy and safety of Pluvicto in combination with SoC (ARPI + ADT) vs. SoC alone in adult patients with PSMA-positive mHSPC3. Patients randomized to the SoC alone arm are allowed to crossover to receive Pluvicto, upon confirmation of radiographic progression by blinded independent review committee (BIRC) and per the discretion of the treating physician3. The primary endpoint is rPFS, defined as the time to radiographic progression by PCWG3-modified RECIST V1.1 (as assessed by BIRC) or death3. The key secondary endpoint of OS is defined as time to death due to any cause3. About Pluvicto™ (INN: lutetium (177Lu) vipivotide tetraxetan) Pluvicto is an intravenous RLT that combines a targeting compound (a ligand) with a therapeutic radionuclide (a radioactive particle, in this case lutetium-177)5,7. After administration into the bloodstream, Pluvicto binds to PSMA-expressing target cells, including prostate cancer cells that express PSMA, a transmembrane protein5,7. Once bound, energy emissions from the radioisotope damage the target cells and nearby cells, disrupting their ability to replicate and/or triggering cell death7. Pluvicto is the only PSMA-targeted agent approved for PSMA-positive mCRPC and is the first targeted RLT to demonstrate a clinical benefit for patients with PSMA-positive mHSPC1. Novartis is investigating Pluvicto in earlier stages of disease, including oligometastatic prostate cancer (PSMA-DC, NCT05939414). Novartis and radioligand therapy (RLT) Novartis is reimagining cancer care with RLT for patients with advanced cancers. By harnessing the power of targeted radiation and applying it to advanced cancers, RLT is designed to deliver treatment directly to target cells, anywhere in the body8,9. Novartis is investigating a broad portfolio of RLTs, exploring new isotopes, ligands and combination therapies to look beyond gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and prostate cancer and into breast, colon, lung and pancreatic cancer. Novartis has established global expertise, with specialized supply chain and manufacturing capabilities across its network of RLT production sites. To support growing demand for RLTs, we have expanded production capabilities in Millburn (NJ), Zaragoza (Spain), Ivrea (Italy) and a state-of-the-art facility in Indianapolis (IN). In Carlsbad (CA), Novartis is establishing its third US-based RLT manufacturing site to support expanded use of RLTs, create resiliency in its manufacturing network and optimize the delivery of medicines to patients on the West Coast. Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'may,' 'could,' 'trend,' 'potentially,' 'upcoming,' 'progression,' 'progress,' 'investigating,' 'investing,' 'look beyond,' or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for Pluvicto, or regarding potential future revenues from Pluvicto. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Pluvicto will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that Pluvicto will be commercially successful in the future. In particular, our expectations regarding Pluvicto could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. References Data on file. Pluvicto [prescribing information]. Millburn, NJ: Advanced Accelerator Applications USA, Inc.; 2025. An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition). identifier: NCT04720157. Updated March 5, 2025. Accessed June 2, 2025. Oing C, Bristow RG. Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy. ESMO Open 2023l doi: 10.1016/ Sartor O, J. de Bono KN, Chi K, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. NEJM 2021; doi: 10.1056/NEJMoa2107322. Morris M, Castellano D, Herrmann K, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. The Lancet 2024; doi: 10.1016/S0140-6736(24)01653-2. University of Chicago Medicine. Lutetium-177 PSMA Therapy for Prostate Cancer (Pluvicto). Accessed June 18, 2024. Jadvar H. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment [published correction appears in AJR Am J Roentgenol. 2017 Oct;209(4):949. doi: 10.2214/AJR.17.18875]. AJR Am J Roentgenol. 2017;209(2):277-288. doi:10.2214/AJR.17.18264 Jurcic JG, Wong JYC, Knoc SJ, et al. Targeted radionuclide therapy. In: Tepper JE, Foote RE, Michalski JM, eds. Gunderson & Tepper's Clinical Radiation Oncology. 5th ed. Elsevier, Inc. 2021;71(3):209-249 # # # Novartis Media Relations E-mail: [email protected] Novartis Investor RelationsCentral investor relations line: +41 61 324 7944 E-mail: [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Insider
an hour ago
- Business Insider
Nxera Pharma achieves development milestone in collaboration with Eli Lilly
Nxera Pharma announces that it has achieved a development milestone under its multi-target collaboration and license agreement with Eli Lilly (LLY) and Company targeting diabetes and metabolic diseases, resulting in a payment to Nxera. The payment amount is undisclosed under the agreement with Lilly. However, Nxera makes this announcement in accordance with the timely disclosure requirements as the achievement of the milestone represents significant progress in research and development for Nxera. Nxera expects to receive the milestone payment in the third quarter of the fiscal year ending December 2025. Under the terms of the agreement, Nxera is eligible to receive development and commercial milestones totalling up to US$694 million, plus tiered royalties on global sales. Confident Investing Starts Here:
